Check out today’s featured companies who have recently raised a round of funding, and be sure to check out the full list of past healthcare IT fundings.
Synthpop Raises $15 Million Series A to Scale AI that Makes Healthcare More Human
Synthpop, Inc., a healthcare AI company building agentic automation to eliminate administrative bottlenecks in payer, provider, and patient operations, announced today a $15 million Series A, bringing the company’s total funding to $23 million. The round was led by Ansa Capital, with Marco DeMeireles, Co‑Founder & Managing Partner at Ansa, joining Synthpop’s Board of Directors. Defy.vc and Peterson Ventures participated in the round, alongside Storm Ventures and strategic investor Bruce Broussard.
Synthpop unifies document intelligence, payer-aware reasoning, and conversational voice agents into one coordinated system that automates up to 80% of healthcare business processes. These agents integrate directly with EHR, billing, and e-prescribe platforms, and customers use them to handle workflows that range from referrals, prior authorizations, eligibility checks, claims follow-ups, to patient access and more – reducing denials, saving costs, speeding up patient care, and lightening the overall administrative burden. Over the past year, Synthpop has demonstrated significant traction, processing over 2 million patients and now integrating with 8 major EHR systems.
“Point solutions can’t fix operational bottlenecks,” said Elad Ferber, CEO at Synthpop. “Providers need a unified system that understands insurance requirements, handles phone calls naturally, and works seamlessly with their existing software. This funding helps us expand our coverage and deepen integrations so providers can scale their operations and expand access to care.”
Some of the nation’s largest organizations across DME, Fertility, Diagnostics, and more have already seen substantial benefits by adopting Synthpop. Workflows that historically took 40 minutes are now processed in <1 minute at a 5x lower cost than traditional human labor spend, while maintaining complete compliance and transparency.
“Healthcare organizations have long been constrained by highly manual workflows and human capital bottlenecks. AI-native solutions like Synthpop are the only way for them to fulfill rising demand and increased patient expectations,” said Marco DeMeireles, Co‑Founder & Managing Partner at Ansa…
Full release here, originally announced February 3rd, 2026.
Solace Raises $130 Million Series C to Make Healthcare Advocacy a Standard of Care in the U.S.
New Funding Accelerates Solace’s Expansion, Establishing Healthcare Advocacy as Essential Infrastructure for Closing the Gaps Between Diagnosis and Treatment
Solace Health today announced a $130 million Series C funding round led by IVP, accelerating the company’s mission to make advocacy a standard part of care for every patient in the United States. The Series C values Solace at over $1 billion and reflects a growing consensus that healthcare advocacy is no longer optional as costs rise and systems fracture. The round also included participation from existing investors Menlo Ventures, SignalFire, Torch Capital, Inspired Capital, and RiverPark Ventures.
Despite unprecedented healthcare spending, millions of Americans still struggle to access timely, coordinated care, and nearly 40% delay or avoid care altogether due to cost and complexity. These gaps drive missed diagnoses, avoidable hospitalizations, caregiver burnout, and billions in unnecessary spend. Solace exists to close that gap.
Solace is a patient-centric healthcare advocacy layer that sits alongside clinical care. The company connects patients and families with trained healthcare advocates who coordinate care across providers, manage logistics, and surface options that help patients move forward with confidence. By intervening between diagnosis and treatment where patients are most vulnerable, Solace shortens time-to-care, reduces friction, and improves outcomes at scale.
Solace’s model is also designed around the professionals delivering advocacy. By establishing a dedicated advocacy role with clear scope and strong technological support, Solace enables experienced nurses and care specialists to focus on judgment and patient guidance, building durable relationships over time and reinforcing the quality and consistency that better outcomes require.
With this funding, Solace will significantly expand its national network of more than 2,000 experienced advocates serving Medicare and Medicare Advantage members, while accelerating investment in its platform and clinical research. The company will also deepen partnerships with payers and providers to embed advocacy earlier in the care journey where outcomes are most at risk.
Solace was founded by CEO Jeremy Gurewitz and Chief Product Officer Sara Sargent…
Full release here, originally announced February 10th, 2026.
No comments:
Post a Comment